Good morning. Elizabeth Cooney here in wintry Boston, sitting in for Ed Silverman while he appears on a panel far from the Pharmalot campus. Here are some items to start the work week. Share tips here if you’ve got ’em.
A group of top biotech venture capitalists is issuing a stark warning to Congress: They won’t be able to pour money into biotech research if Democrats’ signature drug pricing bill becomes law, STAT reports. “If policies such as those included within H.R. 3, the Lower Drug Costs Now Act, are passed, our ability to continue to invest in future biomedical innovation will be severely constrained, thus crushing the hopes of millions of patient waiting for the next breakthroughs,” the letter states.